Ando Ryoichi, Yama Satomi, Ohnishi Tsuyoshi, Iwamoto Shunsuke, Kimura Hitoshi, Chida Yoshiko, Ishida Yuji, Yamada Kouei, Inagaki Yuichiro, Takayama Masanobu, Tachibana Ken, Kikuchi Kan, Inoue Atsushi, Ohtsuka Masakazu
Department of Nephrology, Musashino Red Cross Hospital, Tokyo, Japan.
Ther Apher Dial. 2014 Jun;18 Suppl 1:2-8. doi: 10.1111/1744-9987.12206.
We previously conducted a multicenter study enrolling 101 dialysis patients with hyperphosphatemia in which lanthanum carbonate (LC) was administered for 2 years. In this study, the administration has been continued for an additional year, and we have evaluated the long-term (a total of 3 years) effects of LC. The average serum phosphorus (P) level was 6.05 mg/dL at the start and decreased to 5.84 mg/dL after 3 years, but no significant differences were observed at both points. The average serum corrected calcium (Ca) level significantly reduced after 3 years (P < 0.001). As results of evaluating the achievement rates with the management target values of serum P, Ca and intact parathyroid hormone (PTH) stated in the Japanese guideline, the achievement rates increased after 3 years. From these results, LC is considered to be a useful P binder that can be used for long-term treatment of hyperphosphatemia, without causing a Ca load.
